Chiara Corti
@CCortiMD
MD, Oncologist from @IEOufficiale @LaStatale • Fellow @DanaFarber @Harvard • Editor @PLOSDigiHealth • @scuolapolitiche 2020 • Epistemic diversity enthusiast.
“We need #women who are so strong they can be #gentle, so #educated they can be #humble, so fierce they can be #compassionate, so #passionate they can be #rational, and so disciplined they can be #free.” ― Kavita N. Ramdas
N1 axillary disease post neoadjuvant chemo in Early Stage Breast Cancer? If clinically N0, SLNB with >= 3 nodes or TAD is fine. Residual ITCs: ALND can be avoided. Residual micromets: ALND could be avoided, still standard for TNBC. Residual macromets: ALND still standard.
📢Reminder! The #HarvardBreastCancerCourse is next week on July 17 & 18! Check out our hashtag to see past speakers and topics. Register today to attend in person or virtually ⬇️⬇️ learn.hms.harvard.edu/programs/breas…
Exercise is medicine. Physically active breast cancer survivors had 31% (95% CI: 25–37%) reduction in risk of breast cancer mortality relative to physically inactive pts. pmc.ncbi.nlm.nih.gov/articles/PMC12…
Pleased to share this interesting review by my friend and colleague, @GuiNaderMarta Adding inavo to palbo+fulvestrant in PIK3CA-mut HR+/HER2– MBC improved PFS & OS but ↑ toxicities (hyperglycemia, stomatitis). Careful pt selection & monitoring essential.
Excellent review: INAVO120 marks a turning point, despite limitations. Previous treatment boundaries are breaking. Triplet combinations — hormonal therapy, CDK4/6 inh and PI3K inh— are now clinically achievable. Early genomic testing matters. ascopubs.org/doi/full/10.12…
Happy to share our latest #review on #neoadjuvantimmunotherapy: an extensive overview of current and emerging data in NSCLC, TNBC, GI + bladder cancers, melanoma and many more: written with close friends and KOLs published today in @NatureCancer @lab_kok doi.org/10.1038/s43018…
@ASCO 📖 Decoding Clinical Trials in #MetastaticBreastCancer: Practical Insights for Optimal Therapy Sequencing pubmed.ncbi.nlm.nih.gov/40367401/ @CCortiMD @hoperugo @stolaney1 #MBC
New study in @ESMO_Open examines clinicopathological features and genomics of ER-positive/HER2-negative #BreastCancer relapsing on adjuvant #abemaciclib. 🔓pubmed.ncbi.nlm.nih.gov/40466434/ ✍️@ChiaCorti @DrDAbravanel @PTarantinoMD @curijoey @TariKingMD @EMittendorfMD @nlinmd @stolaney1
Check out the newest #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (June 1st-6th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch
I think I speak for many when I say we were the lucky & grateful ones to have met you. Your trial on topical diclofenac for preventing capecitabine-associated H&F syndrome made a truly effective and pragmatic impact on clinical practice. Very glad we could also connect online!
Immensely grateful to @stolaney1 and the entire @DFCI_BreastOnc for letting me be part of their team over the past week. Never come across a more humble and down-to-earth individual. The exemplary work done by @DFCI_BreastOnc team is top-notch, ineffable and praise-worthy. Lots…
New in @NEJM - OASIS-4 trial shows elinzanetant significantly ⬇️ vasomotor symptoms from ET in HR+ breast cancer - Week 4: −6.5 vs −3.0 episodes/day - Week 12: −7.8 vs −4.2 episodes/day - Well-tolerated overall Accompanied by an editorial from @AnnPartridgeMD @OncoAlert
Presented at #ASCO25: In the OASIS-4 phase 3 trial involving women taking endocrine therapy for HR-positive breast cancer, elinzanetant (a neurokinin-targeted therapy) significantly reduced the frequency of moderate-to-severe vasomotor symptoms. Full trial results:…
Amazing presentation by my senior Italian colleague @paolazagam on the impact of OFS with adjuvant ET on survival in young BRCA-mutated breast cancer pts. So proud to see female Italian oncologists thrive—huge thanks to all her mentors and her mentor abroad @DrLisaCarey 🙏🏻
Multiple studies looking at neoadjuvant regimens for HER2+ early BC. Looks like THP would suffice for most stage 1 and 2, and Cb not needed. Interesting question as to whether 6 cycles / 18 weeks is > than 4 cycles / 12 weeks. @ASCO #ASCO25 @OncoAlert
Happening Now #ASCO25 Poster Session: Differential genomic landscape of estrogen receptor-low versus ER-positive and ER-negative #MetastaticBreastCancer (#MBC). @CCortiMD 📍Abs 1071 | Poster Bd 50 | Jun 2, 9-12 PM CDT | Hall A
🚨 It’s poster session at #ASCO25: ICYI, please stop by poster board #50 to chat about the differential genomic landscape of ER-low vs ER+ and ER– metastatic #breastcancer. #bcsm @DFCI_BreastOnc @DanaFarberNews @LaStatale Link to the abstract: asco.org/abstracts-pres…
Worthy of plenary
Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:…
This discussion of SERENA-6 trial was excellent. #ASCO25 This doesn’t feel practice changing to me.
Grateful for the acknowledgment! I strongly believe it’s every #healthcare worker’s responsibility to question whether #AI tools intended for clinical use are built on the least biased knowledge base and, more importantly, whether they improve patient outcomes.
Interesting story on radiologists and confidence in AI-review of mammograms ft. Dr Chiara Corti from @DFCI_BreastOnc bostonglobe.com/2025/05/30/bus…
Ribociclib benefits in the adjuvant setting was independent from menopausal status. Natalee updates presented by @KalinskyKevin #ASCO25 #bcsm @matteolambe